AMGN
HealthcareAmgen Inc.
$320.72
$-6.92 (-2.11%)
Jan 5, 2026
Price History (1Y)
Analysis
Amgen Inc. is a healthcare company operating in the drug manufacturers - general industry within the broader healthcare sector. The company has a substantial scale with a market capitalization of $172.70B, annual revenue of $35.97B, and over 28,000 employees. Financially, Amgen exhibits robust profitability with gross margin of 70.1%, operating margin of 34.2%, and profit margin of 19.5%. The company's returns on equity and assets are notable at 81.7% and 7.7%, respectively. However, the debt-to-equity ratio is high at 567.49, indicating significant leverage. Amgen's balance sheet also shows $54.59B in debt and $9.45B in cash. Amgen's valuation metrics indicate a higher P/E ratio of 25.31 with lower forward P/E of 14.61, suggesting some discounting of future earnings. The company has experienced revenue growth of 12.4% year-over-year and earnings growth of 13.6%. Amgen pays out dividends at a rate of 72.6%, corresponding to an unusually high dividend yield of 295.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Visit website →Key Statistics
- Market Cap
- $172.70B
- P/E Ratio
- 25.31
- 52-Week High
- $346.38
- 52-Week Low
- $259.35
- Avg Volume
- 2.65M
- Beta
- 0.45
- Dividend Yield
- 295.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NMS
- Country
- United States
- Employees
- 28,000